StreetInsider.com News Articles

Form 4 Elevance Health, Inc. For: Oct 22 Filed by: Kaye Mark

Fri, 23 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261023/27228216.html

Elevance (ELV) PT Raised to $520 at Bernstein SocGen Group

Fri, 23 Oct 2026 09:27:01 -0400

(Updated - October 23, 2026 9:27 AM EDT)

Bernstein SocGen Group analyst Lance Wilkes raised the price target on Elevance (NYSE: ELV) to $520.00 (from $488.00) while maintaining a Outperform rating.

The analyst commented: "Solid qtr with improving MLR; new President appointed for Carelon; 3Q26 Adj EPS of $6.99 was 49.3% above consensus. The performance benefited from a non-operating benefit of $1.85 per share, but still finished 9.8% above cons excluding the one time benefit. Additionally, the result included one time costs through investments in member experience, medical cost management, and value-based solutions, which we see as masking underlying strength. ELV reiterated

Elevance (ELV) PT Raised to $520 at Bernstein SocGen Group

Fri, 23 Oct 2026 09:27:01 -0400

(Updated - October 23, 2026 9:27 AM EDT)

Bernstein SocGen Group analyst Lance Wilkes raised the price target on Elevance (NYSE: ELV) to $520.00 (from $488.00) while maintaining a Outperform rating.

Elevance (ELV) PT Raised to $495 at TD Cowen

Fri, 23 Oct 2026 08:56:16 -0400

TD Cowen analyst Ryan Langston raised the price target on Elevance (NYSE: ELV) to $495.00 (from $465.00) while maintaining a Buy rating.

Elevance (ELV) PT Raised to $490 at Mizuho

Fri, 23 Oct 2026 06:57:40 -0400

Mizuho analyst Ann Hynes raised the price target on Elevance (NYSE: ELV) to $490.00 (from $470.00) while maintaining a Outperform rating.

Form 144 Elevance Health, Inc. Filed by: Kaye Mark

Thu, 22 Oct 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20261022/27222509.html

Elevance (ELV) PT Raised to $523 at UBS

Thu, 22 Oct 2026 09:15:10 -0400

UBS analyst AJ Rice raised the price target on Elevance (NYSE: ELV) to $523.00 (from $460.00) while maintaining a Buy rating.

Elevance (ELV) PT Raised to $449 at Morgan Stanley

Thu, 22 Oct 2026 08:54:16 -0400

Morgan Stanley analyst Erin Wright raised the price target on Elevance (NYSE: ELV) to $449.00 (from $404.00) while maintaining a Equalweight rating.

Elevance (ELV) PT Raised to $500 at BofA Securities

Thu, 22 Oct 2026 08:12:17 -0400

BofA Securities analyst Kevin Fischbeck raised the price target on Elevance (NYSE: ELV) to $500.00 (from $480.00) while maintaining a Buy rating.

The analyst comments "ELV beat Q3 adj EPS by 10% excluding items. The 2026 adj baseline was raised 2.9% to $26.75, which implies 2027 EPS of at least $29.96, 1.5% above cons. Of note, mgmt. saw upside in Medicaid, MA and exchanges with commercial results in-line. Although ELV is confident in making progress on Medicaid margins in 2027, it indicated that growing 12%+ is not reliant on any one business. Tailwinds to 2027 include: 1) Medicaid margin improvement, 2)

Elevance (ELV) PT Raised to $500 at BofA Securities

Thu, 22 Oct 2026 08:12:17 -0400

BofA Securities analyst Kevin Fischbeck raised the price target on Elevance (NYSE: ELV) to $500.00 (from $480.00) while maintaining a Buy rating.

Elevance (ELV) PT Raised to $485 at Guggenheim

Thu, 22 Oct 2026 07:29:05 -0400

(Updated - October 22, 2026 7:29 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on Elevance (NYSE: ELV) to $485.00 (from $460.00) while maintaining a Buy rating.

The analyst commented: ' ELV reported strong 3Q26 outperformance across all focus areas, with MA product/mix benefits continuing, early positive signs on Medicaid rates, and favorable HIX claims experience, while also shuffling $0.25 of HIX favorability into its earnings baseline. Despite another solid, well-executed print, we suspect investor debates will heat up in context of the multiple ELV deserves on its earnings recovery roadmap, particularly given lingering Medicaid acuity risks. However, it’s difficult

Elevance (ELV) PT Raised to $485 at Guggenheim

Thu, 22 Oct 2026 07:29:05 -0400

(Updated - October 22, 2026 7:29 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on Elevance (NYSE: ELV) to $485.00 (from $460.00) while maintaining a Buy rating.

Elevance (ELV) PT Raised to $500 at Truist Securities

Thu, 22 Oct 2026 07:25:16 -0400

Truist Securities analyst David MacDonald raised the price target on Elevance (NYSE: ELV) to $500.00 (from $475.00) while maintaining a Buy rating.

Elevance (ELV) PT Raised to $455 at RBC Capital

Thu, 22 Oct 2026 07:13:48 -0400

RBC Capital analyst Ben Hendrix raised the price target on Elevance (NYSE: ELV) to $455.00 (from $424.00) while maintaining a Sector Perform rating.

Elevance (ELV) PT Raised to $406 at Baird

Thu, 22 Oct 2026 06:20:57 -0400

Baird analyst Michael Ha raised the price target on Elevance (NYSE: ELV) to $406.00 (from $393.00) while maintaining a Neutral rating.

Elevance (ELV) PT Raised to $472 at Barclays

Thu, 22 Oct 2026 03:38:04 -0400

Barclays analyst Andrew Mok raised the price target on Elevance (NYSE: ELV) to $472.00 (from $469.00) while maintaining a Overweight rating.

Form 10-Q Elevance Health, Inc. For: Sep 30

Wed, 21 Oct 2026 14:15:00 -0400

http://archive.fast-edgar.com/20261021/APV2U22CZ22282Z2222S22ZZGRIKFJX23282

Filed on: October 21, 2026

Elevance Health names Jeff Park as Carelon president

Wed, 21 Oct 2026 07:30:34 -0400

Elevance Health (NYSE: ELV) has appointed Jeff Park as President of Carelon, effective December 1, 2026, according to a company press release.

Park most recently served as President of Waltz Health and, following Waltz Health's merger with EVERSANA, continued leading the Waltz business while supporting enterprise growth and strategy. He has previously held senior leadership roles at OptumRx, Catamaran, WellDyneRx, and Diplomat Pharmacy.

Elevance Health Chief Executive Gail K. Boudreaux said in a statement: "Jeff brings deep healthcare experience and a proven track record of growing businesses, driving execution, and creating value for customers."

Carelon is a subsidiary of Elevance Health that provides

Elevance Health Names Jeff Park President of Carelon

Wed, 21 Oct 2026 07:30:00 -0400

Experienced healthcare executive will lead Carelon’s continued evolution and strategic growth

INDIANAPOLIS--(BUSINESS WIRE)-- Elevance Health (NYSE: ELV) today announced the appointment of Jeff Park as President of Carelon, effective December 1, 2026. In this role, Park will lead Carelon through its next phase of growth, building on its momentum and expanding its ability to improve affordability, enhance the consumer experience, and create greater value for customers and the people it serves.

Park joins Carelon at a time of significant opportunity as demand continues to grow for integrated solutions that improve affordability, simplify the health care experience, and support

Elevance Health Names Jeff Park President of Carelon

Wed, 21 Oct 2026 07:30:00 -0400

Experienced healthcare executive will lead Carelon’s continued evolution and strategic growth

Park joins Carelon at a time of significant opportunity as demand continues to grow for integrated solutions that improve affordability, simplify the health care experience, and support

Elevance Health beats estimates, raises guidance

Wed, 21 Oct 2026 06:23:12 -0400

Investing.com -- Elevance Health Inc. (NYSE: ELV) reported third-quarter results before the open on Wednesday, exceeding analyst expectations.

Adjusted earnings per share were $6.99, compared to the consensus estimate of $4.70. Operating revenue reached $50.4 billion, surpassing the $49.32 billion estimate and rising 0.7% YoY from $50.1 billion in the third quarter of 2025.

The company raised its full-year 2026 adjusted EPS guidance to at least $29.00, above the analyst consensus of $27.24. Elevance also increased its full-year operating cash flow guidance to at least $6.5 billion. The benefit expense ratio improved 70 basis points to 90.6%, driven by better

Elevance Health Inc. (ELV) Tops Q3 EPS by $2.29, Beats on Revenue; Offers FY EPS Guidance

Wed, 21 Oct 2026 06:04:24 -0400

Elevance Health Inc. (NYSE: ELV) reported Q3 EPS of $6.99, $2.29 better than the analyst estimate of $4.70. Revenue for the quarter came in at $50.4 billion versus the consensus estimate of $49.32 billion.

GUIDANCE:

Elevance Health Inc. sees FY2026 EPS of $29.00, versus the consensus of $27.24.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

Elevance Health Inc. (ELV) Tops Q3 EPS by $2.29, Beats on Revenue; Offers FY EPS Guidance

Wed, 21 Oct 2026 06:04:24 -0400

GUIDANCE:

Elevance Health Inc. sees FY2026 EPS of $29.00, versus the consensus of $27.24.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

Form 8-K Elevance Health, Inc. For: Oct 21

Wed, 21 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261021/27212499.html

Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance

Wed, 21 Oct 2026 06:00:00 -0400

3Q 2026 operating revenue of $50.4 billion, up 0.7% from 3Q 2025
3Q 2026 diluted EPS1 of $6.27 and adjusted diluted EPS2 of $6.99; results reflect improved operating performance and a net non-operating benefit of $1.85 per share
FY 2026 diluted EPS1 guidance raised to at least $22.00; adjusted diluted EPS2 guidance raised to at least $29.00 on continued operating momentum
FY 2026 operating cash flow guidance raised to at least $6.5 billion
Investing in capabilities that improve the member experience, strengthen our competitive advantage, and support long-term growth

INDIANAPOLIS--(BUSINESS WIRE)-- Elevance Health, Inc. (NYSE: ELV) reported third quarter 2026 results